Patents by Inventor Benjamin David Auerbach

Benjamin David Auerbach has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10682397
    Abstract: Disclosed herein are novel methodologies of treating fragile X syndrome and related disorders by inhibiting mGlu5-relevant signaling pathways via the reduction of ?-arrestin2 protein levels or the diminution of mGlu5 and ?-arrestin2 protein interactions.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: June 16, 2020
    Assignees: Massachusetts Institute of Technology, Duke University
    Inventors: Benjamin David Auerbach, Mark Firman Bear, Laura Jane Stoppel, Robert J. Lefkowitz
  • Publication number: 20170157218
    Abstract: Disclosed herein are novel methodologies of treating fragile X syndrome and related disorders by inhibiting mG1u5-relevant signaling pathways via the reduction of ?-arrestin2 protein levels or the diminution of mG1u5 and ?-arrestin2 protein interactions.
    Type: Application
    Filed: November 30, 2016
    Publication date: June 8, 2017
    Applicants: Massachusetts Institute of Technology, Duke University
    Inventors: BENJAMIN DAVID AUERBACH, Mark Firman Bear, Laura Jane Stoppel, Robert J. Lefkowitz
  • Publication number: 20120264784
    Abstract: Subjects having elevated signaling of a mammalian target of rapamycin (mTOR) are treated with compositions that include at least one compound that activates a Group 1 mGluR. In an embodiment, the subject has tuberous sclerosis complex (TSC). In an embodiment, the compound is a Group 1 mGluR agonist. In another embodiment, the compound is a Group 1 mGluR positive allosteric modulator.
    Type: Application
    Filed: April 25, 2012
    Publication date: October 18, 2012
    Inventors: Mark F. Bear, Benjamin David Auerbach